|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 96.92 USD | -0.92% |
|
+1.43% | -1.87% |
| 17/04 | Goldman Sachs Adjusts Incyte Price Target to $100 From $98, Maintains Neutral Rating | MT |
| 14/04 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
 | 22 | |||||||
| 28 | |||||||
| 20 | |||||||
| 25 | |||||||
| 16 | |||||||
| 30 | |||||||
| 20 | |||||||
| 11 | |||||||
| 23 | |||||||
| 4 | |||||||
| 23 | |||||||
| 21 | |||||||
| 9 | |||||||
| - | 1 | ||||||
| - | 1 | ||||||
| 12 | |||||||
| 1 | |||||||
| - | - | ||||||
| 5 | |||||||
| Average | 15 | |||||||
| Weighted average by Cap. | 20 |
- Stock Market
- Equities
- INCY Stock
- Sector Incyte Corporation
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition